Celularity Inc. Form 8-K Summary
Business context and reporting period
This is an event-driven filing, not a periodic financial report; it does not provide quarterly or annual operating results. The cover page identifies September 18, 2026 as the report date of the earliest event, while the filing describes financing agreements entered into September 23, the initial closing on September 24, and a filing signature dated September 28, 2026.
Financing, liquidity, and potential dilution
- Celularity may issue up to $25.0 million aggregate principal amount of senior secured convertible notes in two tranches. At the September 24 initial closing, it issued approximately $11.01 million principal amount for approximately $11.01 million in gross cash proceeds, before fees and expenses.
- Tranche 1 permits up to $15.0 million in notes. The initial notes convert at $1.50 per share and were accompanied by warrants initially exercisable at $1.50 for approximately 4.037 million shares. The initial notes are convertible into approximately 7.340 million shares, excluding accrued interest and adjustments. Additional Tranche 1 closings are subject to agreement terms; pricing may be $1.50 or $1.60 per share depending on timing.
- Purchasers may elect through September 30, 2027 to fund a further $10.0 million under Tranche 2. Its notes and warrants would initially be priced at $2.00 per share.
- Notes bear 10% annual interest, compounded annually, with accrued interest payable at maturity, 24 months after each issuance. No cash interest is due before maturity. The rate increases to 15% during an event of default. Conversion-price adjustments include certain below-price issuances, subject to exceptions and a $1.25 minimum; warrants have anti-dilution provisions and the same minimum exercise price. Warrants generally expire after five years.
- The notes are secured by substantially all assets of the Company and certain subsidiaries, subject to exclusions and permitted liens. After release of the security interest for certain prior Trust debt, the notes are intended to have first-priority security, subject to permitted liens. A portion of the initial proceeds repaid amounts under a June 2026 Trust secured loan; the amount repaid is not specified.
- The existing $3.0 million Trust convertible note was amended and restated as a note under the financing, with a $1.50 conversion price, 10% annual interest, and a new 24-month maturity from September 23, 2026. The related restated warrant covers up to 1,258,740 shares at $1.50 and expires September 23, 2031.
- The filing does not provide revenue, profit, cash-flow, margin, total debt, cash balance, or liquidity-runway figures. It also does not provide enough information to quantify total potential dilution relative to shares outstanding.
Material changes and unusual items
- Under a September 18 settlement with Helena Global Investment Opportunities 1 Ltd., the Company issued 700,000 shares upon conversion of $1.197 million of note principal at $1.71 per share, permanently satisfying and cancelling that note. It also issued 2.0 million additional shares as settlement consideration.
- Helena waived the remaining $200,000 of installment payments under the prior settlement and certain asserted liquidated damages. Helena released related liens and security interests. A share-based make-whole provision may require further shares or, in some circumstances, a pre-funded warrant; the outcome depends on performance conditions and the November 16, 2026 closing price. If conditions are met, Helena is to return the portion of the 2.0 million settlement shares it is not entitled to retain.
- Subject to escrow and applicable performance conditions, Helena also agreed to assign the Company $1.25 million principal amount of a $2.5 million NEXGEL, Inc. note, with related interest and rights.
- Geoffrey Ling resigned from the Board effective September 24; the filing states the resignation was not due to disagreement with the Company. Philip A. Barach was appointed director effective that date under a Board Rights Agreement with the Trust. The agreement provides for further board-composition changes and interim restrictions on use of financing proceeds and certain spending commitments.
Outlook, conditions, and risks
- The Company agreed to seek any stockholder approval required under Nasdaq rules for shares issued in the transactions. If approval is not obtained by December 19, 2026, the then-current conversion and exercise prices automatically decrease by 10% on December 20, subject to agreement terms.
- The Company agreed to file a resale registration statement for shares underlying the notes and warrants within 45 calendar days after September 23, 2026 and to use best efforts to obtain effectiveness within specified time periods.
- The settlement requires the Company to become current in its Exchange Act reporting by October 20, 2026. Helena’s rights to retain settlement shares and receive any make-whole securities depend on specified performance conditions.
- Potential investor risks include interest and repayment obligations, default-rate interest, secured claims against Company assets, conversion and warrant dilution, anti-dilution adjustments, Nasdaq stockholder-approval conditions, and restrictions on certain expenditures while board changes are implemented.
Important facts for investors to verify
- Whether additional Tranche 1 or Tranche 2 financing closes, and the resulting cash proceeds, fees, and obligations.
- Required Nasdaq stockholder approval status and the effect of the December 2026 price-reduction provision.
- Outstanding share count and fully diluted share impact, including accrued interest, warrants, anti-dilution adjustments, and Helena make-whole securities.
- Completion of the Helena settlement performance conditions, any return or issuance of shares, and receipt of the NEXGEL note assignment.
- Use of financing proceeds, repayment of prior Trust debt, current liquidity, and the Company’s ability to meet note maturities.
- Timely completion of Exchange Act reporting and resale registration obligations.